BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Idefirix (Imlifidase) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Idefirix (Imlifidase)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05753930-884@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Idefirix (Imlifidase): Phase 2 readout est. (NCT05753930)
DESCRIPTION:Idefirix (Imlifidase)\, phase 2.\nStudy: Imlifidase Prior to Ki
 dney Transplant in Highly Sensitised Children\nEstimated primary completio
 n: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 imlifidase#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05753930
URL:https://assetmemo.bio/drug/imlifidase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05937750-884@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Idefirix (Imlifidase): Phase 3 readout est. (NCT05937750)
DESCRIPTION:Idefirix (Imlifidase)\, phase 3.\nStudy: A Long-term Follow-up 
 Trial of Patients Previously Treated With Imlifidase Prior to Kidney Trans
 plantation and a Non-comparative Transplanted Patient Group\nEstimated pri
 mary completion: 30 April 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/imlifidase#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05937750
URL:https://assetmemo.bio/drug/imlifidase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
